Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Translation, Cultural Adaptation, and Evaluation of a Brazilian Portuguese Questionnaire to Estimate the Self-Reported Prevalence of Gluten-Related Disorders and Adherence to Gluten-Free Diet.

Arámburo-Gálvez JG, Carvalho Gomes I, André TG, Beltrán-Cárdenas CE, Macêdo-Callou MA, Braga Rocha ÉM, Mye-Takamatu-Watanabe EA, Rahmeier-Fietz V, Figueroa-Salcido OG, Cárdenas-Torres FI, Ontiveros N, Cabrera-Chávez F.

Medicina (Kaunas). 2019 Sep 15;55(9). pii: E593. doi: 10.3390/medicina55090593.

2.

Management of colorectal peritoneal metastases: Expert opinion.

Abboud K, André T, Brunel M, Ducreux M, Eveno C, Glehen O, Goéré D, Gornet JM, Lefevre JH, Mariani P, Pinto A, Quenet F, Sgarbura O, Ychou M, Pocard M.

J Visc Surg. 2019 Aug 26. pii: S1878-7886(19)30127-4. doi: 10.1016/j.jviscsurg.2019.08.002. [Epub ahead of print]

PMID:
31466831
3.

Chemotherapy in resected neuroendocrine carcinomas of the digestive tract: a national study from the French Group of Endocrine Tumours (GTE).

Pellat A, Walter T, Augustin J, Hautefeuille V, Hentic O, Do Cao C, Lièvre A, Coriat R, Hammel P, Dubreuil O, Cohen R, Couvelard A, André T, Svrcek M, Baudin E, Afchain P.

Neuroendocrinology. 2019 Aug 21. doi: 10.1159/000502825. [Epub ahead of print]

PMID:
31430756
4.

Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma.

Derieux S, Svrcek M, Manela S, Lagorce-Pages C, Berger A, André T, Taieb J, Paye F, Voron T.

Dig Liver Dis. 2019 Aug 16. pii: S1590-8658(19)30712-1. doi: 10.1016/j.dld.2019.07.010. [Epub ahead of print]

PMID:
31427088
5.

Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma.

Alhenc-Gelas M, Cohen R, Cervera P, Vaillant JC, André T.

Case Rep Gastrointest Med. 2019 Jul 10;2019:8598635. doi: 10.1155/2019/8598635. eCollection 2019.

6.

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.

Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A.

Lancet Oncol. 2019 Sep;20(9):1263-1272. doi: 10.1016/S1470-2045(19)30276-1. Epub 2019 Jul 19.

PMID:
31331699
7.

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T.

Clin Colorectal Cancer. 2019 Sep;18(3):200-208.e1. doi: 10.1016/j.clcc.2019.04.006. Epub 2019 May 3.

PMID:
31311761
8.

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.

Auclin E, André T, Taieb J, Banzi M, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, Vernerey D.

Br J Cancer. 2019 Aug;121(4):312-317. doi: 10.1038/s41416-019-0521-7. Epub 2019 Jul 12.

PMID:
31296923
9.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.

Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.

PMID:
31268130
10.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.

Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Benetkiewicz M, Banzi M, Louvet C, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, André T, Vernerey D.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1153-1161. doi: 10.1158/1055-9965.EPI-18-0867.

PMID:
31263053
11.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delaloge S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC.

Bull Cancer. 2019 Sep;106(9):759-775. doi: 10.1016/j.bulcan.2019.04.013. Epub 2019 Jun 25. French.

PMID:
31253356
12.

Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms.

Turpin A, Labreuche J, Fléjou JF, Andre T, de Gramont A, Hebbar M.

Dig Liver Dis. 2019 Aug;51(8):1198-1201. doi: 10.1016/j.dld.2019.05.019. Epub 2019 Jun 18. No abstract available.

PMID:
31221547
13.

Is it permissible to undertake surgery for adrenal metastases of esophageal adenocarcinomas?

Bui QL, Paye F, Siksik JM, Cohen R, André T.

J Visc Surg. 2019 Jun;156(3):275. doi: 10.1016/j.jviscsurg.2019.04.008. Epub 2019 May 12. No abstract available.

PMID:
31088734
14.

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J.

Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.

PMID:
30889492
15.

Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.

Lupinacci RM, Bachet JB, André T, Duval A, Svrcek M.

Surg Oncol. 2019 Mar;28:121-127. doi: 10.1016/j.suronc.2018.11.019. Epub 2018 Nov 26. Review.

PMID:
30851885
16.

Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.

Taieb J, André T, Auclin E.

Cancer Treat Rev. 2019 May;75:1-11. doi: 10.1016/j.ctrv.2019.02.002. Epub 2019 Feb 26. Review.

PMID:
30849607
17.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.

Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, Merabtene F, Dumont S, Sauvanet A, Hammel P, Cros J, André T, Bachet JB, Bardier A, Douard R, Meatchi T, Peschaud F, Emile JF, Cojean-Zelek I, Laurent-Puig P, Taieb J.

Br J Cancer. 2019 Apr;120(7):697-702. doi: 10.1038/s41416-019-0415-8. Epub 2019 Mar 6.

PMID:
30837681
18.

Science and evolution.

Russo CAM, André T.

Genet Mol Biol. 2019 Feb 28;42(1):120-124. doi: 10.1590/1678-4685-gmb-2018-0086. Print 2019 Jan-Mar.

19.

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A.

Int J Oncol. 2019 Apr;54(4):1433-1445. doi: 10.3892/ijo.2019.4709. Epub 2019 Feb 1.

PMID:
30720091
20.

[Microsatellite instability (MSI): best predictor of effectiveness of immune checkpoint inhibitors (ICKi)? Focus on MSI by Bulletin du Cancer].

André T.

Bull Cancer. 2019 Feb;106(2):91-93. doi: 10.1016/j.bulcan.2019.01.009. Epub 2019 Jan 31. French. No abstract available.

PMID:
30711199
21.

[Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].

Cohen R, Heran M, Pudlarz T, Hilmi M, Tournigand C, André T, Rousseau B.

Bull Cancer. 2019 Feb;106(2):151-161. doi: 10.1016/j.bulcan.2018.09.008. Epub 2019 Jan 11. Review. French.

PMID:
30638897
22.

[Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer].

Bay JO, André T, Caux C, Evrard S, Gonçalves A, L'Allemain G, Magné N, Orbach D, Penel N, Rodrigues M, Thariat J, Thiery-Vuillemin A, Wislez M; Comité de Rédaction du Bulletin du Cancer.

Bull Cancer. 2019 Jan;106(1):12-23. doi: 10.1016/j.bulcan.2018.12.005. Epub 2019 Jan 3. Review. French.

PMID:
30612698
23.

[Lynch syndrome: What is new?]

Pellat A, Netter J, Perkins G, Cohen R, Coulet F, Parc Y, Svrcek M, Duval A, André T.

Bull Cancer. 2019 Jul - Aug;106(7-8):647-655. doi: 10.1016/j.bulcan.2018.10.009. Epub 2018 Dec 4. Review. French.

PMID:
30527816
24.

Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy.

Tauber M, Cohen R, Laly P, Josselin L, André T, Mekinian A.

Clin Rheumatol. 2019 Feb;38(2):601-602. doi: 10.1007/s10067-018-4373-y. Epub 2018 Nov 19.

PMID:
30456528
25.

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.

Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, André T, Svrcek M, Duval A.

JAMA Oncol. 2019 Apr 1;5(4):551-555. doi: 10.1001/jamaoncol.2018.4942.

PMID:
30452494
26.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J.

Clin Colorectal Cancer. 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19.

PMID:
30415988
27.

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.

Cohen R, Pellat A, Boussion H, Svrcek M, Lopez-Trabada D, Trouilloud I, Afchain P, André T.

Bull Cancer. 2019 Feb;106(2):137-142. doi: 10.1016/j.bulcan.2018.09.004. Epub 2018 Oct 14. Review.

PMID:
30327191
28.

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.

Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B.

World J Clin Oncol. 2018 Sep 14;9(5):110-118. doi: 10.5306/wjco.v9.i5.110.

29.

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, André T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A.

Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.

PMID:
30190299
30.

Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights.

Cohen R, Sroussi M, Pilati C, Houry S, Laurent-Puig P, André T.

J Gastrointest Oncol. 2018 Aug;9(4):E23-E27. doi: 10.21037/jgo.2018.05.10.

31.

Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability.

Jonchere V, Marisa L, Greene M, Virouleau A, Buhard O, Bertrand R, Svrcek M, Cervera P, Goloudina A, Guillerm E, Coulet F, Landman S, Ratovomanana T, Job S, Ayadi M, Elarouci N, Armenoult L, Merabtene F, Dumont S, Parc Y, Lefèvre JH, André T, Fléjou JF, Guilloux A, Collura A, de Reyniès A, Duval A.

Cell Mol Gastroenterol Hepatol. 2018 Jun 13;6(3):277-300. doi: 10.1016/j.jcmgh.2018.06.002. eCollection 2018.

32.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C.

Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.

PMID:
30042063
33.

Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.

Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M; RENAPE Network.

Ann Surg Oncol. 2018 Oct;25(11):3271-3279. doi: 10.1245/s10434-018-6631-2. Epub 2018 Jul 5.

PMID:
29978366
34.

[Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].

Vaflard P, Ederhy S, Torregrosa C, André T, Cohen R, Lopez-Trabada D.

Bull Cancer. 2018 Jul - Aug;105(7-8):707-719. doi: 10.1016/j.bulcan.2018.05.005. Epub 2018 Jun 28. Review. French.

PMID:
29960638
35.

Eight weeks of resistance training in conjunction with glutathione and L-Citrulline supplementation increases lean mass and has no adverse effects on blood clinical safety markers in resistance-trained males.

Hwang P, Morales Marroquín FE, Gann J, Andre T, McKinley-Barnard S, Kim C, Morita M, Willoughby DS.

J Int Soc Sports Nutr. 2018 Jun 27;15(1):30. doi: 10.1186/s12970-018-0235-x.

36.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
37.

Prognostic value and characteristics of N1c colorectal cancer.

Bouquot M, Creavin B, Goasguen N, Chafai N, Tiret E, André T, Flejou JF, Parc Y, Lefevre JH, Svrcek M.

Colorectal Dis. 2018 Sep;20(9):O248-O255. doi: 10.1111/codi.14289. Epub 2018 Jun 30.

PMID:
29894583
38.

Restrictive Breathing Mask Reduces Repetitions to Failure During a Session of Lower-Body Resistance Exercise.

Andre TL, Gann JJ, Hwang PS, Ziperman E, Magnussen MJ, Willoughby DS.

J Strength Cond Res. 2018 Aug;32(8):2103-2108. doi: 10.1519/JSC.0000000000002648.

PMID:
29847532
39.

[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]

André T, Taieb J; Pour l’intergroupe PRODIGE (GERCOR, Fédération française de cancérologie digestive, et Unicancer) et pour la Fondation ARCAD (Aide et recherche encancérologie digestive).

Bull Cancer. 2018 Jun;105(6):546-547. doi: 10.1016/j.bulcan.2018.04.002. French. No abstract available.

PMID:
29776587
40.

Rectal and anal canal neuroendocrine tumours.

André TR, Brito M, Freire JG, Moreira A.

J Gastrointest Oncol. 2018 Apr;9(2):354-357. doi: 10.21037/jgo.2017.10.01.

41.

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

Auclin E, André T, Taieb J, Benetkiewicz M, de Gramont A, Vernerey D.

Eur J Cancer. 2018 Jul;97:55-56. doi: 10.1016/j.ejca.2018.03.032. Epub 2018 May 3. No abstract available.

PMID:
29731226
42.

Publisher Correction: Control of laser plasma accelerated electrons for light sources.

André T, Andriyash IA, Loulergue A, Labat M, Roussel E, Ghaith A, Khojoyan M, Thaury C, Valléau M, Briquez F, Marteau F, Tavakoli K, N'Gotta P, Dietrich Y, Lambert G, Malka V, Benabderrahmane C, Vétéran J, Chapuis L, El Ajjouri T, Sebdaoui M, Hubert N, Marcouillé O, Berteaud P, Leclercq N, El Ajjouri M, Rommeluère P, Bouvet F, Duval J-, Kitegi C, Blache F, Mahieu B, Corde S, Gautier J, Ta Phuoc K, Goddet JP, Lestrade A, Herbeaux C, Évain C, Szwaj C, Bielawski S, Tafzi A, Rousseau P, Smartsev S, Polack F, Dennetière D, Bourassin-Bouchet C, De Oliveira C, Couprie M-.

Nat Commun. 2018 May 2;9(1):1814. doi: 10.1038/s41467-018-04299-1.

43.

Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M.

Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8.

44.

Control of laser plasma accelerated electrons for light sources.

André T, Andriyash IA, Loulergue A, Labat M, Roussel E, Ghaith A, Khojoyan M, Thaury C, Valléau M, Briquez F, Marteau F, Tavakoli K, N'Gotta P, Dietrich Y, Lambert G, Malka V, Benabderrahmane C, Vétéran J, Chapuis L, El Ajjouri T, Sebdaoui M, Hubert N, Marcouillé O, Berteaud P, Leclercq N, El Ajjouri M, Rommeluère P, Bouvet F, Duval J-, Kitegi C, Blache F, Mahieu B, Corde S, Gautier J, Ta Phuoc K, Goddet JP, Lestrade A, Herbeaux C, Évain C, Szwaj C, Bielawski S, Tafzi A, Rousseau P, Smartsev S, Polack F, Dennetière D, Bourassin-Bouchet C, De Oliveira C, Couprie ME.

Nat Commun. 2018 Apr 6;9(1):1334. doi: 10.1038/s41467-018-03776-x. Erratum in: Nat Commun. 2018 May 2;9(1):1814.

45.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.

J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.

PMID:
29620995
46.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T.

N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.

47.
48.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
49.

Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status.

Mésange P, Bouygues A, Ferrand N, Sabbah M, Escargueil AE, Savina A, Chibaudel B, Tournigand C, André T, de Gramont A, Larsen AK.

Clin Cancer Res. 2018 Jun 1;24(11):2548-2558. doi: 10.1158/1078-0432.CCR-17-3187. Epub 2018 Feb 28.

50.

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, André T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A.

Ann Oncol. 2018 May 1;29(5):1099-1107. doi: 10.1093/annonc/mdy064.

PMID:
29438451

Supplemental Content

Support Center